Daré Bioscience (DARE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Executive summary
Supplement details engagement of Okapi Partners LLC to assist with proxy solicitation for the 2026 annual meeting scheduled for June 11, 2026.
Okapi will provide strategic advice and may solicit proxies through various communication methods.
Okapi's fee is $15,000 plus additional fees and expenses, with indemnification for certain liabilities.
The company will bear all costs of proxy solicitation, including reimbursement to intermediaries forwarding materials.
Voting matters and shareholder proposals
Proxies are being solicited for the 2026 annual meeting and any adjournments or postponements.
Board of directors and corporate governance
Directors and employees may participate in proxy solicitation without additional compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Daré Bioscience
- Women's health biotech pursues dual-path market strategy amid financial and listing risks.DARE
Registration filing - New product launches and key clinical milestones drive a pivotal growth phase.DAREInvestor update
- Two women's health products launch in 2026, backed by a robust pipeline and strong funding.DARECorporate presentation
- Revenue rose and losses narrowed, but going concern and Nasdaq delisting risks remain.DAREQ2 2026
- Commercial launches and clinical milestones mark a pivotal growth phase, backed by strong funding.DAREVirtual Investor Closing Bell
- Imminent launches and clinical milestones position the pipeline for strong near-term growth.DARETD Cowen 46th Annual Health Care Conference
- All eight proposals, including director elections and stock plan amendments, were approved.DAREAGM 2026
- Annual meeting on June 11, 2026, with virtual voting and emphasis on shareholder participation.DAREProxy filing
- First product revenue expected June 2026, but ongoing viability depends on new capital.DAREQ1 2026